

Please add new claims 18-20, as follows:

18. (New) The therapeutic agent according to claim 2, wherein the disease is selected from

- a) a secondary hyperparathyroidism caused by PTH and
- b) a primary hyperparathyroidism caused by PTH.

19. (New) The therapeutic agent according to claim 10, wherein the disease caused by PTH or PTHrP-cytokine cascade is chosen from septicemia, cachexia, inflammation, hemopathy, calcium metabolism abnormality, and autoimmune disease.

20. (New) The agent according to claim 14, wherein the substance that binds to a ligand of PTH receptor or PTHrP receptor to inhibit binding between the ligand and the receptor is chosen from an anti-PTHrP antibody and anti-PTH antibody.

REMARKS

Claims 1-20 are now pending in this application. Applicants have filed this Preliminary Amendment to ensure that the pending claims meet with U.S. practice requirements. Specifically, Applicants have eliminated improper multiple dependency and clarified grammar in the claims. These Amendments do not change the scope of the claims in any way and are not substantive, but are only made to more particularly define the invention and conform with U.S. requirements on multiple dependency. New claims 18, 19, and 20, are based on claims 6, 11, and 15, respectively. Applicants request the consideration of this application and examination of these claims.

If there is any fee due in connection with the filing of this Preliminary
Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: March 26, 2002

By: Rebecca M. McNeill
Rebecca M. McNeill
Reg. No. 43,796

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 L Street, NW
Washington, DC 20005
202 462 4000
Fax 202 462 4400
www.finnegan.com

APPENDIX TO THE AMENDMENT

This appendix illustrates the specific changes made to the amended claims. Deletions from the claims are shown using a strikeout font and square brackets, while additions are shown using underlining.

1. (Amended) A therapeutic agent for a disease caused by PTH or PTHrP~~[-~~
~~which comprises, as]~~ comprising an active ingredient~~[-]~~ chosen from
 - a) an agonist or antagonist of binding to a PTH receptor or PTHrP
receptor, ~~[or]~~ and
 - b) a substance ~~[binding]~~ that binds to a ligand of ~~[the]~~ either receptor to promote
or inhibit binding between the ligand and the receptor.
2. (Amended) The therapeutic agent according to claim 1, wherein the
disease caused by PTH or PTHrP is ~~[primarily]~~ a disease other than hypercalcemia.
3. (Amended) [A] The therapeutic agent of claim 1, wherein the therapeutic
agent is a QOL improving agent for alleviating a symptom of a disease caused by PTH
or PTHrP~~[-, which comprises, as an active ingredient, an agonist or antagonist binding to
a PTH receptor or PTHrP receptor, or a substance binding to a ligand of the receptor to
promote or inhibit binding between the ligand and the receptor].~~
4. (Amended) [A] The therapeutic agent of claim 1, wherein the therapeutic
agent is for a syndrome associated with malignancy caused by PTHrP~~[-, which
comprises, as an active ingredient, an agonist or antagonist binding to a PTH receptor~~

~~or PTHrP receptor, or a substance binding to a ligand of the receptor to promote or inhibit binding between the ligand and the receptor].~~

5. (Amended) The therapeutic agent according to claim 4, wherein the syndrome associated with malignancy is ~~[selected]~~ chosen from ~~[the group consisting of]~~ at least one of digestive system disorders, proteometabolism abnormality, saccharometabolism abnormality, lipid metabolism abnormality, anorexia, hematological abnormality, electrolyte abnormality, immunodeficiency and pain.

6. (Amended) The therapeutic agent according to claim 1 ~~or 2~~, wherein the disease is chosen from at least one of

a) a secondary hyperparathyroidism caused by PTH ~~or~~ and

b) a primary hyperparathyroidism caused by PTH.

7. (Amended) ~~[An alleviation]~~ The therapeutic agent of claim 1, wherein the therapeutic agent is is for a central nervous system disease caused by PTH or PTHrP~~[- which comprises, as an active ingredient, an agonist or antagonist binding to a PTH receptor or PTHrP receptor, or a substance binding to a ligand of the receptor to promote or inhibit binding between the ligand and the receptor].~~

8. (Amended) The ~~[alleviation]~~ therapeutic agent according to claim 7, wherein the central nervous system disease is ~~[selected]~~ chosen from ~~[the group consisting of]~~ at least one of dyssomnia, neuropathy, nervous symptom disorder, brain metabolism abnormality, cerebral circulation abnormality, autonomic imbalance, and endocrine system abnormality with which central nervous system is associated.

9. (Amended) ~~[An alleviation]~~ The therapeutic agent of claim 1, wherein the therapeutic agent is for a disease caused by PTH or PTHrP-cytokine cascade [, ~~which comprises, as an active ingredient, an agonist or antagonist binding to a PTH receptor or PTHrP receptor, or a substance binding to a ligand of the receptor to promote or inhibit binding between the ligand and the receptor~~].

10. (Amended) The ~~[alleviation]~~ therapeutic agent according to claim 9, wherein the cytokine is ~~[selected]~~ chosen from ~~[the group consisting of]~~ IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL13, IL- 15, G-CSF, GM-CSF, M-CSF, EPO, LIF, TPO, EGF, TGF- α , TGF- β , FGF, IGF, HGF, VEGF, NGF, activin, inhibin, a BMP family member, TNF and IFN.

11. (Amended) The ~~[alleviation]~~ therapeutic agent according to claim 9 ~~[or 40]~~, wherein the disease caused by PTH or PTHrP-cytokine cascade is ~~[selected]~~ chosen from ~~[the group consisting of]~~ at least one of septicemia, cachexia, inflammation, hemopathy, calcium metabolism abnormality, and autoimmune disease.

12. (Amended) [A] The therapeutic agent of claim 1, wherein the therapeutic agent is a central nervous system regulator [, ~~which comprises, as an active ingredient, an agonist or antagonist binding to a PTH receptor or PTHrP receptor, or a substance binding to a ligand of the receptor to promote or inhibit binding between the ligand and the receptor~~].

13. (Amended) [A] The therapeutic agent of claim 1, wherein the therapeutic agent is a cytokine network regulator [, ~~which comprises, as an active ingredient, an agonist or antagonist binding to a PTH receptor or PTHrP receptor, or a substance~~

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1400 I Street, NW
Washington, DC 20005
202 462 4000
Fax 202 462 4400
www.finnegan.com

~~binding to a ligand of the receptor to promote or inhibit binding between the ligand and the receptor].~~

15. (Amended) The agent according to any one of claims 1 to [14] 13, wherein the substance [~~binding~~] that binds to a ligand of PTH receptor or PTHrP receptor to inhibit binding between the ligand and the receptor is [~~selected~~] chosen from [~~the group consisting of~~] an anti-PTHrP antibody and anti-PTH antibody.

16. (Amended) The agent according to claim 15, wherein the substance [~~binding~~] that binds to a ligand of PTH receptor or PTHrP receptor to inhibit binding between the ligand and the receptor is an anti-PTHrP antibody.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 L Street, NW
Washington, DC 20005
Tel 202 462 4000
Fax 202 462 4400
www.finnegan.com